KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Asset Writedowns and Impairment (2023 - 2024)

Historic Asset Writedowns and Impairment for Vir Biotechnology (VIR) over the last 2 years, with Q4 2024 value amounting to $11.0 million.

  • Vir Biotechnology's Asset Writedowns and Impairment rose 30007.25% to $11.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 40007.25%. This contributed to the annual value of $14.6 million for FY2024, which is 5065.23% up from last year.
  • Per Vir Biotechnology's latest filing, its Asset Writedowns and Impairment stood at $11.0 million for Q4 2024, which was up 30007.25% from $2.8 million recorded in Q4 2023.
  • Vir Biotechnology's 5-year Asset Writedowns and Impairment high stood at $11.0 million for Q4 2024, and its period low was $2.8 million during Q4 2023.